Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01538095 · ClinicalTrials.gov registry record · Phase 1
Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System Tumors
A Phase 1 study of Solid Neoplasm and Central Nervous System Neoplasm, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 37
- Enrollment target
- 20
- Study locations
NCT01538095: Completed Phase 1 study of Solid Neoplasm and Central Nervous System Neoplasm, sponsored by National Cancer Institute (NCI).
NCT01538095 is a Phase 1 study of Solid Neoplasm and Central Nervous System Neoplasm that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 37 participants, below the 940-participant average among 12 other Solid Neoplasm trials with a reported enrollment target (96% lower). The trial reports 20 study locations across 16 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01538095, a Phase 1 study of Solid Neoplasm and Central Nervous System Neoplasm, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 37 participants
- Enrollment target
- 20
- Study locations
Study Summary
This phase I trial studies the side effects and best dose of trebananib in treating patients with solid tumors that has returned after a period of improvement or does not respond to treatment, including central nervous system tumors. Trebananib may stop the growth of tumor cells by blocking blood flow to the tumor.
Primary Outcome
A descriptive summary of all toxicities will be reported.
Conditions Studied
Interventions
- OTHER Laboratory Biomarker Analysis
- PROCEDURE Dynamic Contrast-Enhanced Magnetic Resonance Imaging
- OTHER Pharmacological Study
- BIOLOGICAL Trebananib
Study Locations (20)
Pennsylvania
- Children's Hospital of Philadelphia - Philadelphia
- Childrens Oncology Group - Philadelphia
- Children's Hospital of Pittsburgh of UPMC - Pittsburgh
Alabama
- Children's Hospital of Alabama - Birmingham
- University of Alabama at Birmingham Cancer Center - Birmingham
California
- Children's Hospital of Orange County - Orange
- UCSF Medical Center-Parnassus - San Francisco
District of Columbia
- Children's National Medical Center - Washington D.C.
Georgia
- Children's Healthcare of Atlanta - Egleston - Atlanta
Illinois
- Lurie Children's Hospital-Chicago - Chicago
Indiana
- Riley Hospital for Children - Indianapolis
Michigan
- C S Mott Children's Hospital - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2012-02 |
| Est. Completion | 2016-04 |
| Phase | Phase 1 |
What the finished NCT01538095 record still lists
NCT01538095 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 37 participants, a relatively small participant target, below the 940-participant average among 12 other Solid Neoplasm trials with a reported enrollment target (96% lower).
The record links to 2 conditions, with Solid Neoplasm appearing as the primary indexed condition, and to 4 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT01538095 names 20 study sites across 16 states, led by Pennsylvania, Alabama, California.
Frequently Asked Questions
What is clinical trial NCT01538095 about?
NCT01538095 is a clinical study titled "Trebananib in Treating Younger Patients With Relapsed or Refractory Solid Tumors, Including Central Nervous System Tumors". This phase I trial studies the side effects and best dose of trebananib in treating patients with solid tumors that has returned after a period of improvement or does not respond to treatment, including central nervous system tumors. Trebananib may stop the growth of tumor cells by blocking blood fl...
What is the current status of trial NCT01538095?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 37 participants. The study started on 2012-02. Estimated completion is 2016-04.
What conditions does trial NCT01538095 study?
This clinical trial studies the following conditions: Solid Neoplasm, Central Nervous System Neoplasm.
What interventions are being tested in trial NCT01538095?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Dynamic Contrast-Enhanced Magnetic Resonance Imaging (PROCEDURE), Pharmacological Study (OTHER), Trebananib (BIOLOGICAL).
Who is sponsoring clinical trial NCT01538095?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01538095 being conducted?
This trial has 20 study locations across Alabama, California, District of Columbia, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01538095's enrollment target sits among peer trials
37 9th of 12 higher than 4 of 12 other Solid Neoplasm trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Solid Neoplasm trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTF
RECRUITING · Phase 1
-
Veliparib, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Non-Hodgkin Lymphoma
ACTIVE NOT RECRUITING · Phase 1
-
Pazopanib Hydrochloride in Treating Patients With Advanced or Refractory Solid Tumors
ACTIVE NOT RECRUITING · Phase 1
-
Tipifarnib and Erlotinib Hydrochloride in Treating Patients With Advanced Solid Tumors
COMPLETED · Phase 1
-
Selumetinib and Cyclosporine in Treating Patients With Advanced Solid Tumors or Advanced or Metastatic Colorectal Cancer
COMPLETED · Phase 1
-
Ilorasertib in Treating Patients With CDKN2A-deficient Advanced or Metastatic Solid Cancers That Cannot Be Removed by Surgery
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02800486 · 37 participants · Phase 2
Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA
- NCT03173937 · 37 participants · Phase 1
Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome
- NCT03295227 · 37 participants · Phase 1
Pembrolizumab in Treating Participants With Unresectable Thymoma or Thymic Cancer
- NCT03401047 · 37 participants · Early Phase 1
Study to Assess Potential Impairments in Estradiol Augmentation of Gonadotropin Secretion in Polycystic Ovary Syndrome
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia